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ABBREVIATIONS 
 
AD: Alzheimer’s Disease 
b-FGF: basic Fibroblast Growth Factor 
BSA: Bovine Seroalbumin 
ACN: Acetonitrile 
CNS: Central Nervous System 
DMEM: Dulbecco’s Modified Essential Medium 
DTT: Di-thiotreitol 
EAE: Experimental Autoimmune Encephalomyelitis 
FDR: False Discovery Rate 
GO: Gene Ontology 
HBSS: Hank’s Balanced Salt Solution 
HD: Huntington’s Disease 
HRP: Horse Radish Peroxidase 
IgM: Immunoglobulin M 
KEGG: Kyoto Encyclopedia of Genes and Genomes 
LC-MS/MS: Liquid chromatography-tandem mass spectrometry 
LIMMA: Linear Model for Microarray Analysis 
MS: Multiple Sclerosis 
MS/MS: Tandem Mass Spectometry 
MSA: Multiple System Atrophy 
MWB: Miltenyi Wash Buffer 
NDS: Normal Donkey Serum 
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Neo: Neonatal 
OPC: Oligodendrocyte Progenitor Cell 
PBS: Phosphate Buffered Saline 
PC: Principal Component  
PCA: Principal Component Analysis 
PD: Parkinson’s Disease 
PDGF-aa: Platelet Derived Growth Factor AA 
PFA: Paraformaldehyde 
PSM: Peptide-to-spectrum matches 
PVDF: Polyvinylidene fluoride 
RNA-seq: RNA sequencing 
RT: Room Temperature 
TBS: Tris-Buffered Saline 
TBST: Tris-Buffered Saline with 0.1% Tween 
TEAB: Triethylammonium bicarbonate 
TFA: Trifluoroacetic acid 
TMT: Tandem mass tag 
V: Volts  
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ABSTRACT 
 
Following central nervous system (CNS) demyelination, adult oligodendrocyte progenitor cells (OPCs) 
can differentiate into new myelin-forming oligodendrocytes in a regenerative process called 
remyelination. While remyelination is very efficient in young adults, its efficiency declines 
progressively with ageing. Here we performed proteomic analysis of OPCs freshly isolated from the 
brains of neonate, young and aged female rats. Approximately 50% of the proteins are expressed at 
different levels in OPCs from neonates compared to their adult counterparts. The amount of myelin-
associated proteins, and proteins associated with oxidative phosphorylation, inflammatory responses 
and actin cytoskeletal organization increased with age, while cholesterol-biosynthesis, transcription 
factors and cell cycle proteins decreased. Our experiments provide the first ageing OPC proteome, 
revealing the distinct features of OPCs at different ages. These studies provide new insights into why 
remyelination efficiency declines with ageing and potential roles for aged OPCs in other 
neurodegenerative diseases.  
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INTRODUCTION 
 
Oligodendrocyte progenitor cells (OPCs) are the cells responsible for generating new myelin sheath-
forming oligodendrocytes in the regenerative process of remyelination. Remyelination restores rapid 
conduction of action potentials and metabolic support to axons,  and prevents axonal degeneration 
in chronic demyelinating diseases such as multiple sclerosis (MS) (1). During remyelination, adult OPCs 
activate, divide, migrate and differentiate into myelin forming oligodendrocytes in response to a 
demyelinating insult (2-4). Remyelination is a highly efficient process in young adults: however, as 
with all regenerative processes, its efficiency declines progressively with ageing (5). A combination of 
environmental changes, such as the capacity of phagocytic cells to remove myelin debris (6-8), as well 
as cell-intrinsic epigenetic changes (9), contribute to the age-associated decline in remyelination 
efficiency (10). This decline is thought to be a major determinant of disease progression in MS 
patients, and is proposed to be a significant factor in the transition into the largely untreatable 
progressive phase of the disease (11).  
 
Several brain related RNA-Seq datasets have been published recently (2, 12, 13), including a recent 
RNA dataset comparing OPCs at different ages (14, 15). However, the correlation between RNA 
expression and the expression of proteins can be low (16, 17): hence, there is clear need for a 
comprehensive quantitative analysis of ageing OPCs proteome. Other publications have addressed 
the proteome of OPCs derived from human embryonic stem cells (18), the proteome of OPCs during 
differentiation to oligodendrocytes (19)  and the proteome of various CNS specific cell types in the 
mouse brain, including oligodendrocytes (17). However, none of these have compared the changes in 
OPCs associated with ageing, which is a key factor in remyelination failure during disease progression 
(5, 10). To address the changes in protein abundance observed within ageing OPCs, we performed a 
comprehensive quantitative proteomic analysis of neonatal, young adult and aged rat OPCs. The OPC 
proteomes we have delineated represent a new and important resource to understand the age-
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related changes that underlie remyelination failure, which will help develop identify remyelination-
enhancing approaches and define the role of OPCs in other age-related diseases. 
 
MATERIAL AND METHODS 
 
Oligodendrocyte progenitor cell isolation 
OPC were isolated from neonatal (P0-P2), 3-4 months old and 15-18 months old Sprague Dawley rats. 
Briefly, rats were euthanized by overdose of intraperitoneal injection of Pentoject and the decapitated 
following schedule 1 procedures (Animal Scientific Procedure Act 1986). The brains were removed 
from the skull and put in to “Hibernate A” (prepared in-house) (20). Meninges were removed and the 
brains were cut into small pieces (about 1 mm3). The brains were digested with a papain solution 
containing papain (33U/mL) and DNAse (0.04mg/mL) in “Hibernate A” for 40 min at 35 °C. Following 
tissue digestion papain was washed out with Hank’s Balanced Salt Solution (HBSS) (-\-) (Gibco) via 
centrifugation. The tissue was then triturated with a polished glass Pasteur pipette in “Hibernate A” 
with 1X B27 (Gibco) and 2 mM sodium pyruvate (Gibco). After trituration, the single cell suspension 
was passed through a 70 µm strainer and centrifuged for 20 min at 800 x g in a 22.5% Percoll (GE 
Healthcare) solution with DMEM F12(Gibco). Following centrifugation Percoll was removed by 
aspiration and the cells were washed with HBSS (-/-) (Gibco). Cells were incubated with anti-A2B5 
antibody (Millipore, MAB312) for 25 min at 4 °C (2 µg of antibody per 107 cells) in wash buffer (Miltenyi 
Wash Buffer [MWB] = 0.5% BSA, 2 mM sodium pyruvate and 2 mM EDTA in 1X PBS). Excess antibody 
was washed with HBSS (-/-) and cells were incubated with secondary IgM-microbeads (Miltenyi Biotec) 
for 15 min at 4 °C (20 µl per 107 cells) in MWB. Excess antibody was again removed by washing with 
HBSS (-/-) and cells were magnetically sorted following the manufacturer’s instructions (Miltenyi 
Biotech). Cells were eluted with OPC media (DMEM F12, 2 mM sodium pyruvate, 60 µg N-acetyl-
cysteine (Sigma-Aldrich), 5 µg/ml Insulin (Gibco), 21 mM D-Glucose (Sigma-Aldrich), 50 µg/ml apo-
transferrin (Sigma-Aldrich), 16.1 µg/ml putrescine (Sigma-Aldrich), 40 ng/mL sodium–selenite (Sigma-
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Aldrich) and 60 ng/mL progesterone (Sigma-Aldrich). Upon OPC removal cells were incubated with 2ul 
of Biotin-MOG antibody per 107cells (R and D systems) for 25min at 4°C in 500µL MWB to label 
oligodendrocytes. Excess antibody was washed with HBSS (-/-) and cells were incubated with 
secondary IgM-microbeads (Miltenyi Biotec) for 15 min at 4 °C (20 µl per 107 cells) in MWB. Excess 
antibody was again removed by washing with HBSS (-/-) and cells were magnetically sorted following 
the manufacturer’s instructions (Miltenyi Biotech). Oligodendrocytes were also eluted with OPC 
media.  
 
Proteome sample preparation 
Experimental Design and Statistical Rationale 
OPCs isolated from neonatal (P0-P2), 3-4 months old and 15-18 months old rats were processed as 
depicted below. Each biological replicate and condition consisted of cells isolated from independent 
rats. A sample size of six biological replicates was used for each age (neonatal, young and aged OPCs) 
providing us with sufficient numbers to accommodate variability. The samples were labelled using 
TMT 10 plex (ThermoFisher Scientific) in which each sample was labelled with a different isotype to 
allow the distinction of the proteome of each sample. The 6 biological sample were divided into two 
different TMT 10 plexes (named as multiplex 1 and 2) to enable labelling of all the samples avoiding a 
potential plate effect and to provide relative quantitation across the three ages. Multiplex 1 included 
neonatal 1-3, young 1-3 and aged 1-3 sample, while multiplex 2 included neonatal 4-6, young 4-6 and 
aged 4-6. A sample consisting of pooled material from all replicates and conditions was labelled with 
the 10th TMT tag with the intent of minimizing the number of missing values between multiplexes, but 
was not used for statistical analysis.  Furthermore, each multiplex containing three biological 
replicates of each age was pre-fractionated as describe below and each fraction ran twice in different 
rounds of LC-MS to increase the proteome coverage. We used LIMMA (Linear Model for Microarray 
Analysis) (23) statistical analysis due to its robustness in dealing with the number of missing values 
and variability encountered on high-throughput quantitative proteomic studies of primary cells as 
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ours. Neonates were used as control condition except when comparing young vs aged rats where 
young was the control.  
 
Sample digestion and TMT labelling 
Cells obtained by magnetic cell sorting were pelleted by centrifugation and supernatant was removed. 
The cell pellet was lysed using lysis buffer (8 M urea, 100 mM triethylammonium bicarbonate [TEAB] 
pH 8.0) (Life-Technologies) followed by freeze-thawing in dry ice and ultrasonic bath incubation. Each 
lysate was immediately reduced with 20 mM dithiothreitol (DTT) (Sigma-Aldrich) in TEAB at RT for 60 
min, alkylated with 40 mM iodoacetamide (Sigma-Aldrich) in the dark for 60 min at room temperature 
(RT) and digested overnight at RT with 1 µg endoproteinase Lys-C (Promega). The following day, the 
solution was diluted to a final urea concentration of 1 M and 1 µg of modified trypsin (Promega) per 
100 µg of cell lysate was added and incubated for 3 h at RT. The samples were acidified with 
trifuoroacetic acid (TFA) (Life Technologies) (0.1% (v/v) final concentration) and debris were pelleted 
by centrifugation at 15,000 × g for 10 min and supernatant frozen at -80 o C until peptide concentration 
and clean-up. 
 
PorosOligo R3 (Life-Technologies) resin was equilibrated in 0.1% TFA. Each sample was desalted by 
sequentially incubating for 5 min with occasional vortexing with 20 µL of slurry (about 10 µL resin). 
The samples were then spun down and the supernatant transferred to a fresh microtube with another 
20 µL slurry. This step was repeated 3 times. Peptide-loaded resins were combined and packed into 
p200 tips over a 3M Empore C8 “plug” (about 1 cm long), washed twice with 50 µL 0.1% TFA and 
eluted with 200 µL 60% acetonitrile (ACN) (adapted from Rappsilber et al. 2003 (21)) and quantified 
using QubitTM (Life Technologies). The volume equivalent to 12 µg of peptides (equivalent to the 
amount of peptide in the lowest yielding condition) were transferred to new microtube to be dried 
down before TMT-labelling. 
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Samples were labelled according to manufacturer`s instructions (ThermoFisher Scientific) with minor 
modifications. Briefly, each dry desalted sample was resuspended in 122.5 µL 100 mM TEAB and each 
TMT label (0.8 mg) resuspended and mixed in 41 µL of pure acetonitrile, then mixed for labelling. 
Samples were labelled for one hour at RT, quenched with 5% hydroxylamine for 15 min and 
multiplexed. Each multiplex was then dried and stored at -80 o C for pre-fractionation for total 
proteome analysis.  
 
Alkaline reverse-phase pre-fractionation and LC-MS/MS analysis 
TMT-10plex labelled peptides from OPCs were combined and fractionated using the alkaline reversed-
phase chromatography (22) on Dionex Ultimate RSLC system. Separation was carried out on an 
XBridge BEH C18 column (2.1 x 100 mm, 5 µm, 130 Å) (Waters) using a gradient of acetonitrile (2 to 
98%) in 10 mM TEAB with a flow rate of 300 µl/min and a running buffer pH=10. Ninety-six fractions 
were collected and concatenated into 18 fractions (Fig. S1) and concentrated to dryness using a 
speedvac with a chilled vacuum trap and stored at -80 °C. 
 
Eighteen fractionated peptide samples were analyzed in replicate on an Orbitrap Fusion Tribrid 
(Thermo Scientific) mass spectrometer interfaced with Dionex Ultimate 3000 nanoRSLC system. 
Nanospray LC system comprised of a 20 mm enrichment column (ReproSil-Pur 120 C18-AQ, 7µm, Dr. 
Maish, Ammerbuch-Entringen, Germany) and a Picofrit (New Objective) analytical column (ReproSil-
Pur 120 C18-AQ, 2.4 µm, 50cm length). Peptides were separated using a gradient of acetonitrile with 
0.1% formic acid up to 80% over a period of 110 min. TMT labelled peptides were analyzed using the 
following data dependent acquisition parameters: Scan range for full MS, m/z 400-1600, resolution 
120,000 (200 m/z), charge state(s) 2-7, higher collision dissociation fragmentation (The fragmentation 
mode was a MS/MS fragmentation of top 15 most intense peptide ion peaks fragmented through 
higher energy collisional dissociation (HDC) with 35% energy) at 60,000 resolution, precursor isolation 
window m/z 1.3 with m/z 0.3 offset. Fragmented peptides were excluded for 30 seconds, 
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monoisotopic selection precursor (MIPS) was enabled with constant internal calibration using 
fluoranthene ion. 
 
Mass spectrometry data were analyzed using Proteome Discoverer 2.1 (PD) (Thermo Fisher Scientific) 
software with search engines Mascot v2.6.0, Amandav2.1.5.4882 and Sequest HTv.1.1.0.158 nodes. 
Data was searched using latest Uniprot Rattus norvegicus protein database with common laboratory 
contaminants included (2016_03 version with 30030 entries including Rattus norvegicus and common 
laboratory contaminant sequences). Search parameters included 2 missed cleavage sites, oxidation 
(M) and deamidation (N, Q) as variable modifications. Tandem mass tag (229.163Da) at N-terminus 
and lysine residue and carbamidomethylation on cysteine residue were set as fixed modifications. The 
mass tolerances on precursor and fragment masses were set at 10 ppm and 0.05 Da, respectively. 
False discovery rate (FDR) cut-off value was set at 0.01. Unique peptide spectrum matches with 
protein information and non-normalized reporter ion intensity was exported and used for statistical 
analysis. 
 
Statistical analysis of TMT-labelled samples 
Statistical analysis of TMT labelled samples was performed with RStudioÒ software. The data from 
the time course analysis consisted of exported peptide-to-spectrum matches (PSMs) from two 
multiplexes containing three biological replicates each (a total of 6 biological replicates). Identification 
results from technical replicates and/or fractions were merged and any repeated protein groups were 
removed. PSMs having ≥50% isolation interference were removed. PSMs from proteins from the 
common contaminant database were removed. The false discovery rate (FDR) for PSM assignments 
was calculated against a decoy database using Percolator v2.05 node. PSMs with missing value in one 
or more conditions within a biological replicate were removed. The intensity values of each sample 
and each TMT label were log2-transformed and then subjected to median sweeping on the log2 
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intensity data by each plate which provides a protein abundance value for further LIMMA (Linear 
Model for Microarray Analysis) statistical analysis (23).  
 
LIMMA analysis provides sufficient power to deal with low replicate numbers and additional missing 
values (24). We therefore carried out unpaired LIMMA analysis comparing all and corrected them for 
multiple testing using the R function provided within VSClust (25). All proteins with q-values below 
0.05 (5% FDR) and log2 change over 0.6 (more than 1.5 fold change) when compared with neonates 
were considered to be regulated. In the case of young adult and aged OPC comparison, all proteins 
with q-values below 0.05 (5% FDR) and log2 change over 0.6 (more than 1.5 fold change) were 
considered significantly regulated.  
 
Downstream bioinformatics analysis 
All protein identification data were mapped to gene symbols using UniProt version 2016_03 (26). 
Annotation for Gene Ontology (GO) pathways such as biological processes, molecular function, 
cellular compartment as well as Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways was 
performed using DAVID (27). When analyzing the GO terms of the total protein groups detected, the 
whole proteome included in DAVID for Rattus norvegicus was used as background using Benjamini-
Hochberg (28). The statistical test PCA clustering analysis was performed using the Log2 transformed 
protein intensity. For the cluster analysis, we calculated the log2 protein intensity mean over all 
biological replicate values for each condition of those proteins with q-value < 0.05 and log2 change 
over 0.6 (more than 1.5 fold change) when compared neonatal OPCs with young and aged OPCs. Fuzzy 
c-means clustering (29) was applied using the “FcmClusterPEst.R” R function 
(https://bitbucket.org/veitveit/vsclust/src/master/ (25)) and “Mfuzz” R library. We determined the 
value of the fuzzifier and obtained the number of clusters according to Schwämmle and Jensen (30) 
(Table S3). The GO term analysis for the different clusters obtained with Fuzzy c-means clustering as 
well as for the protein groups with more than 1.5-fold change expression between young and aged 
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OPCs were obtained with DAVID, using the total protein groups detected in our proteome as 
background. For the heatmap, the Z score from each age category was used. The Z score was 
calculated using the scale function within RStudio® software. The heatmaps were calculated using the 
“pheatmap” R package from Kolde (https://cran.r-project.org/web/packages/pheatmap/ from the R 
Bioconductor tool set and the protein groups shown in each heatmap were obtained from the 
corresponding DAVID GO term shown in the tittle of each heatmap. To analyse GO terms of the 
differentially expressed proteins in the different aged group, each list was uploaded to DAVID and 
compared to the total proteome detected in the ageing OPC proteome. Then, to elaborate the list of 
proteins involved in each of the GO terms, the Uniprot accession protein list provided by DAVID was 
used. The GO terms and the Uniprot accession protein lists associated to each GO term are provided 
in the Table S5 and the fold enrichment of the GO terms that were significantly enriched in the 
category Biological processes (Fig. S3), KEGG pathway (Fig. S4), Cellular component (Fig. S5), or 
Molecular function (Fig. S6) in each of the clusters was represented using a heatmap value for the fold 
enrichment in comparison to the total proteome, which was used as background. The GO term 
network for proteins differentially regulated between young and aged proteins was created using the 
Cytoscape application BINGO (31). In Fig. S7, the different GO biological processes that are associated 
are linked with a grey line. The size of the node indicates the number of proteins amongst the 
regulated proteins that are involved in that GO term. The bigger the node the higher the number or 
proteins. Each node is then divided in 2 colours, blue and orange. Blue indicates proteins that are 
downregulated in aged OPCs and orange proteins that are upregulated in aged OPCs. Again, the size 
of each colour is associated to the number of proteins. 
 
The correlation coefficient between RNA expression from young and aged OPCs and the proteome of 
young and aged OPCs was performed as follows: RNAseq data (GSE134765) was pre-processed 
through sortMeRNA (Kopylova et al., 2012) to filter out ribosomal RNA reads, adapter was trimmed 
and quality paired reads were extracted using Trimmomatics (32). Rat cDNA (Rnor_6.0) was indexed 
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and reads were quantified using Salmon quasi mode (33). Salmon output was processed through 
tximport (34) and Deseq2 (35) and normalised length scaled TPM counts were calculated. Normalized 
log2 transformed values of transcript levels were used for correlation analysis with log2 transformed 
proteomic data set (15).  
 
Ensemble gene IDs corresponding to Uniport protein IDs were extracted. Genes for which expression 
value was not determined (‘NA’) in any one sample were removed. Finally, 6110 genes for ‘young’ 
OPC samples and 6101 genes for ‘aged’ OPC samples remained. For each gene, a correlation 
coefficient (Biweight midcorrelation or bicor) between transcript levels and protein levels was 
estimated and the corresponding Student p-value was determined using bicorAndPvalue function (36) 
in ‘R’. The advantage of bicor over Pearson’s correlation coefficient is based on its robust 
measurement in presence of outliers. p-value was adjusted using FDR (Benjamini-Hochberg) and the 
adjusted p-value <0.05 was considered significant.  
 
Western blot analysis 
Protein lysate was mixed with NuPAGE loading buffer and NuPAGE reducing agent (Life Technologies) 
and boiled for 10 min at 95 °C. Five µg of protein lysate were loaded into Bolts 4-12% gels 
(LifeTechnologies). Electrophoresis gel was run at 120 volts (V) for 90 min and then gels were 
transferred onto a methanol pre-activated PVDF membrane (Millipore). The transfer was done using 
1X Bio-Rad transfer buffer with 20% of ethanol at 100V for 90 min. Upon transfer the membranes 
were blocked with Blocking buffer (TBS blocking agent 1:1 (Li-Cor) with TBS (Fischer Scientific)-0.1% 
Tween (Sigma-Aldrich)) for 1 h at RT. Membranes were incubated overnight at 4 °C with the different 
antibodies (Rabbit MOBP (Abbexa, abx002902) 1:500; Rat MBP (Serotec, MCA490S) 1:500; Mouse 
PADI2 (Proteintech, 66386-1-lg) 1:500; Goat FABP5 (Cell Signalling Technologies, 39926) 1:500; Mouse 
CNPase (Sigma-Aldrich, C5922) 1:500; Goat MOG (R and D systems, AF2439) 1:1000; Rabbit PLP 
(Abcam, ab28486) 1:500; Mouse CRYAB (Abcam, ab13496) 1:500; Rabbit proteasome 19S (Abcam, 
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ab137109), alpha tubulin (1:1000)(Millipore, T9026). Following antibody incubation membranes were 
washed with TBS-0.1% Tween (TBST) three times for 10 min. Membranes were then incubated with 
fluorophore conjugated secondary antibodies (Li-Cor) for 2h at RT and developed using Li-Cor 
developing machine. Western blot analysis was performed measuring the integrated density through 
the Li-Cor software and normalized by the signal of HRP conjugated β-actin (Sigma-Aldrich). Statistical 
analysis was performed with GraphPad Prism version 8.0. First, normality was tested and if the 
number of samples was too low, normality test using residuals was performed. If samples were 
normally distributed 1 way, ANOVA with Sidak’s multiple comparisons test was performed and if 
samples were not normally distributed samples were analysed using Kruskal Wallis and Dunn’s 
Multiple Comparison Tests. Statistics were represented as follows: ns (not significant), *<p<0.05; 
**p<0.01, ***p<0.001 and ****p<0.0001. 
 
Immunocytochemistry 
Cells were plated on poly-D-lysine coated coverslips at a density of 15,000 cells / 9mm coverslips for 
adults and 2,000 cells / 9 mm coverslip in the case of neonates. Cell were cultured with OPC media 
supplemented with 1 ng/mL PDGF-aa and 1 ng/mL b-FGF in the case of OPCs. After 6 days in vitro cells 
were fixed with 4% PFA for 10 min and blocked with 5% normal donkey serum (NDS) (Sigma-Aldrich) 
with 0.01% Triton X-100 (Sigma-Aldrich) in PBS for 1h at RT. Cells were incubated for 1 h at RT with 
the corresponding antibodies (Goat-anti MOBP (Abbexa, abx002902)1:500; Mouse PADI2 
(Proteintech, 66386-1-lg) 1:500; Goat FABP5 (Cell Signalling Technologies, 39926) 1:500; Mouse 
CRYAB (Abcam, ab13496) (1:500), Rabbit anti-Claudin 11 (Abcam, ab53041) 1:500, Goat anti-MMOG 
(R and D systems, AF2439) 1:500)  in 5% NDS with 0.01% Triton-X-100 (Sigma-Aldrich). Following 
washing, fluorescently labelled secondary antibodies (Life Technologies) were used in a 1:500 dilution 
in 5% NDS with 0.01% Triton-X for 1 h at RT. Anti-A2B5 antibody (Millipore, MAB312, 1:500) was 
incubated sequentially to the secondary antibody incubation to avoid cross-reactivity. Nuclei were 
stained with Hoechst (2 µg/mL) (Sigma-Aldrich) for 5 min followed by two washes with PBS prior to 
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mounting the coverslips with Fluoromount G (Southern Biotech). Statistical analysis was performed 
with GraphPad Prism version 8.0. First, normality was tested and if the number of samples was too 
low normality test using residuals was performed. If samples were normally distributed 1 way, ANOVA 
with Sidak’s multiple comparisons test was performed and if samples were not normally distributed 
samples were analysed using Kruskal Wallis and Dunn’s Multiple Comparison Tests. Statistics were 
represented as follows: ns (not significant), *<p<0.05; **p<0.01, ***p<0.001 and ****p<0.0001. 
 
Flow cytometric analysis 
Cells were isolated by magnetic cell sorting. The positive fraction was subjected to staining as follows: 
106 cells were collected in media, spun down at 350 x g for 5min and washed once with PBS. Cells were 
resuspended in 1:100 Zombie Violet (Biolegend, 423113) and incubated for 15 min at RT in the dark. 
Cells were then topped up with PBS1X and pelleted by centrifugation. Cell pellets were re-suspended 
and incubated in 10% fetal calf serum in PBS for blocking. Then cells were pelleted and re-suspended 
in primary antibodies for 30 min except for A2B5-PE (Miltenyi, 130-093-581), which was added in the 
last 10 min of the incubation. Cells were washed with PBS - 0.5% BSA and pelleted by centrifugation. 
Cell pellets were re-suspended in the appropriate secondary antibodies solution in 5% fetal calf serum 
in PBS, incubated 15 min at RT and then washed with PBS-0.5% BSA, centrifuged and resuspended in 
0.5mL “Flow media” (2 mM sodium pyruvate (Life Technologies), 4% SOS (Cell Guidance Systems) and 
10 µg/mL insulin (Gibco) in “Hibernate A”). The primary antibodies used were; anti- CD11B/C PerCP-
Cy5.5 Clone OX-42(Biolegend, 201819), anti-rat erythroid cells Clone OX83 (Biologend, 250402), A2B5-
PE (Miltenyi Biotec, 130-093-581) and goat-MOG (R and D Systems, AF2439). The secondary 
antibodies used include anti-goat Alexa Fluor 647 (Life Technologies) and Pe-Cy7 (Biolegend). 
Statistical analysis was performed with GraphPad Prism version 8.0 for A2B5+MOG- population as that 
is our population of interest. Due to being working with percentages samples were analysed using 
Kruskal Wallis and Dunn’s Multiple Comparison Tests. Statistics were represented as follows: ns (not 
significant), *<p<0.05; **p<0.01, ***p<0.001 and ****p<0.0001. 
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Immunohistochemistry 
Rats were terminally anaesthetized and fixed by intracardiac perfusion using 4% (w/v) PFA. Brains 
were removed, post-fixed in 4% (w/v) PFA overnight at 4°C, cryoprotected with 20% (w/v) sucrose for 
24–48h, embedded and frozen in OCT medium, and stored at −80°C. Tissues were sectioned at 12μm 
and collected onto poly-D-lysine-coated glass slides. 12µm cryo-sections were dried for 1h at RT and 
then rehydrated in PBS. After rehydration, slides were washed 3x 5 min with TBS-0.25% Tween-20 
(Sigma-Aldrich). Sections were then exposed to 1X Citrate Buffer pH 6.0 at 90C for 5min and then the 
sections were let to cool down at room temperature for 30min. Sections were then washed 3x 5 min 
with TBS-0.25% Tween-20 (Sigma-Aldrich). After wash sections were permeabilised for 30min with 1% 
Triton X-100 (Sigma-Aldrich) and then blocked with 10% NDS and 0.25% Tween-20 for 1h at RT. After 
blocking, slides were incubated with primary antibodies in 1% NDS in TBS-0.25% Tween-20 (Sigma-
Aldrich) overnight at 4℃ (Rabbit anti-OLIG2, 1:500 (AB9610, Millipore); Goat anti-PDGFRa (R and D 
systems, AF1062 ); Rabbit anti-proteasome 20S (Abcam, ab22673)(1:200) or Rabbit anti-PFDN5 
(Abcam, ab129116)(1:200). Slides were then incubated with the appropriate Alexa FluorÒ secondary 
antibodies 1:500 (Life Technologies) for 2h at RT. Nuclei were stained with Hoechst (2µg/mL, Sigma-
Aldrich) for 5min at RT, before the coverslips were mounted using Prolong Gold (Life-technologies). 
Per-cell intensity measurements in immunofluorescent sections were quantified using CellProfiler 
(v3.1.8) and CellProfiler Analyst software. First, Hoechst+ nuclei were detected using the CellProfiler 
“IdentifyPrimaryObjects” module and various intensity features were measured within the PDGFRα 
channel from the region surrounding each nucleus. PDGFRα+ cells were distinguished from PDGFRα- 
cells within CellProfiler Analyst, using a supervised learning approach. The PDGFRα+ cells were then 
identified within CellProfiler, and the mean intensity within the local area was measured for each cell 
in the channel of interest (PFDN5 or 20S proteasome). 
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RESULTS 
 
Generating proteomes of acutely isolated OPCs  
To assess differences in the proteome of OPCs at different ages, we isolated OPCs using magnetic cell 
sorting to select for A2B5+ cells from neonatal (P2), young (3-4 months old) and aged (15-18 months 
old) female rats based on the higher prevalence of MS in women than in men (37). An antibody against 
A2B5 was used for OPC selection because i) the high yield and consistency of isolation of adult OPCs 
(1 million cells per adult brain) and ii) the age-associated decrease in expression of other OPC markers 
such as PDGFRA (Fig. 1A). The three ages were selected for the following reasons: (i) developmental 
myelination occurs during neonatal stages, and OPCs isolated during this period have been extensively 
studied in vitro (38-40); (ii) 3-4 months is the adult rodent age where remyelination is highly efficient 
(5); and (iii) 15-18 months old is the age at which remyelination is already impaired and is also slightly 
over half of the life-span of rats in captivity. Therefore, this can be regarded as close to the age at 
which the majority of MS patients generally transition from relapsing-remitting to progressive MS (5, 
41). We termed the OPCs in each group as neonatal, young and aged OPCs, reflecting the age of the 
animal from which they were isolated rather than making any inference about the age of individual 
isolated cells. 
 
To determine the quality of the OPC isolation, we compared the purity of the samples isolated in each 
age group using a panel of antibodies to detect erythroid cells (Clone OX83), microglia (CD11b), 
oligodendrocytes (MOG) and OPCs (A2B5). While in neonates over 90% of the live cells were A2B5+ 
cells with little microglia or red blood cells, in adults (young and aged OPCs) the samples were 
contaminated with 26% of CD11b+ microglia, 2% of A2B5+MOG+ early differentiated oligodendrocytes, 
0.4% of A2B5-MOG+ oligodendrocytes and 15% of red blood cells (Fig. 1B).  
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To determine the differences between the neonatal, young and aged OPC proteome we analysed six 
animals (each treated as an independent biological replicate) for each age group. Cells were lysed 
immediately after isolation and lysates were subjected to two-step Lys-C/trypsin digestions and 
resulting peptides were labelled with TMT-10plex and combined (multiplexed), where peptides 
coming from each animal were marked with a different mass tag. The resulting multiplexed peptides 
were fractionated and concatenated into 18 fractions (Fig. S1A) and subjected to liquid 
chromatography-tandem mass spectrometry (LC-MS/MS)(22). The six animals from each of the 3 age 
groups were divided equally into two different multiplexed LC-MS/MS analyses. These two 
multiplexes showed a high correlation in the log2 changes between young and neonatal or aged and 
neonatal OPC samples, while this correlation was significantly lower in the log2 changes between aged 
and young OPCs. These data suggest there was no batch effect in the analysis and the decreased 
correlation between the log2 change ration between aged and young OPCs in multiplex 1 and 2 reflects 
age-associated intrinsic variability of primary cells (Fig. 1C). The peptide spectra were analysed using 
Proteome Discoverer 2.1 and identified searching against UniProt Rattus norvegicus version 2016_03 
database (26) with maximum threshold of 1% false discovery rate (FDR) at protein and peptide level. 
Quantitation of relative protein expression changes was based on the signal of the TMT tags used to 
label the OPCs arising from each animal/age. We only accepted protein groups with at least two high 
confidence peptides identified, from which at least one was unique to that protein. We detected 7480 
protein groups (Table S1) (Fig. 1D), with an average of 11 peptides per protein and an average 
coverage per protein of 25%. From the total proteins, 6767 were detected in both plates, while 476 
were detected only in plate 1 and 314 in plate 2 (Fig. 1E). We analysed the tissue enrichment of the 
whole proteome, which covered a large portion of brain specific proteins (28) (adjusted p-value 
5.3*10-14) (Fig. S1B). Although protein and RNA often show a poor correlation with each other, with a 
high degree of variability of the correlation coefficient depending on the protein (17), this relationship 
has not been extensively examined in OPCs. Thus, we performed a correlation analysis between the 
proteome and RNA transcript levels in young and aged OPCs (15). This analysis revealed, a low linear 
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correlation between transcripts and proteins. We obtained a correlation coefficient between -0.5 and 
0.5 in most cases, however the statistical significance was below the FDR threshold (0.05) (Fig. 1F, G). 
 
We then assessed the expression of oligodendrocyte lineage markers looking at the log2 protein 
intensity, accomplished by plotting the reporter intensities for each condition after normalisation and 
peptide to protein aggregation based on median values. Oligodendrocyte lineage cell markers such as 
OLIG2 and SOX10 (Fig. 2A), as well as OPC markers PDGFRA, CSPG4, SOX2 and GPR17, were expressed 
in all three groups: neonatal, young and aged OPCs (Fig. 1A, 2B). The expression of some of these 
markers decreased with ageing, corroborating mRNA expression (2). In contrast, the recently 
identified OPC marker ITPR2 (42) as well as CSPG4, which is expressed by other CNS resident cell types 
such as perivascular cells (43, 44) and ageing/reactive microglia (45, 46), had stable expression across 
the age groups.  
 
After examining for the expression of OPC markers, we next validated the accuracy of the expression 
changes detected. Four proteins that significantly change expression with ageing were selected - 
MOBP, PADI2, CRYAB, and FABP5, and their expression in each age group was assessed by western 
blot (Fig. 3A-C). MOBP (1-way ANOVA p=0.0144*, Sidak’s Multiple comparison test neonatal vs young 
p=0.92, neonatal vs aged p=0.0199*, young vs aged p=0.0506), PADI2 (1-way ANOVA p=0.0281*, 
Sidak’s Multiple comparison test neonatal vs young p=0.54, neonatal vs aged p=0.0284*, young vs 
aged p=0.21) and CRYAB Kruskal-Wallis p=0.0012*, Dunn’s Multiple comparison test neonatal vs 
young p=0.0589, neonatal vs aged p=0.0089**, young vs aged p=0.99) are significantly enriched with 
ageing being statistically significant especially when comparing neonatal and aged OPCs. FABP5 on 
the other hand, significantly decreases its expression with ageing similar to what was observed in the 
proteome (1-way ANOVA p=0.0028**, Sidak’s Multiple comparison test neonatal vs young p=0.007**, 
neonatal vs aged p=0.0049**, young vs aged p=0.979) (Fig. 3C). Similarly, the expression of each 
protein per A2B5+ cell was also assessed by immunohistochemistry, where the proteins show similar 
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trends to the proteome (Fig. 3D and E, Fig. S2). CRYAB shows a statistically significant increase (1-way 
ANOVA p=0.0238*, Sidak’s Multiple comparison test neonatal vs young p=0.9760, neonatal vs aged 
p=0.0372*, young vs aged p=0.0598) while PADI2 (1-way ANOVA p=0.4194), MOBP (1-way ANOVA 
p=0.0565) and FABP5 (1-way ANOVA p=0.3555) show non-significant trends (Fig.3E). These results 
corroborated the abundant changes obtained by high-throughput proteomic analysis.  
 
The neonatal OPC proteome is distinct from that of adult counterparts 
To better understand how the OPC proteome changes with ageing, principal component analysis (PCA) 
was performed based on the log2 protein intensity. PCA analysis showed that neonatal OPCs cluster 
separately from young and aged OPCs. The distinction between young and aged OPCs was not clear, 
due to neonatal OPCs dominating the first (PC1) and second principal components (PC2) (Fig. 4A). 
However, when PCA analysis was performed with only young and aged OPCs, they were clearly 
discriminated from each other (Fig. 4B). These results were also observed when analysing the 
correlation of the biological replicates.  There was a positive correlation between the replicates within 
each age group and also between the proteome of young and aged OPCs, while the neonatal OPC 
proteome correlated negatively with young and aged OPC proteome (Fig.4C).  
 
We next investigated the protein expression differences between the three age groups. To determine 
which of these expression changes was significant, unpaired “LIMMA” (Linear Model for Microarray 
Analysis) analysis was performed (23). Taking into account the differences in purity between neonatal 
and adult OPCs (young and aged) (Fig. 1B), a high stringency analysis was applied: only those proteins 
present in at least 5 out the 6 biological replicates were considered for statistical analysis (6842 
proteins out of the 7481 total proteins) and of these, only proteins having a q value below 0.05 (5% 
FDR) and fold change over 1.5 (Log2 change over 0.6), were regarded as significantly regulated. We 
detected 3620 proteins significantly regulated between neonatal and young OPCs, 3702 between 
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neonatal and aged OPCs, while only 89 proteins were differentially expressed between young and 
aged OPCs. (Fig. 4D, E; Table S2).  
 
To characterise how proteins change their expression from neonate to young and aged OPCs, these 
were first grouped using unsupervised fuzzy c-means clustering (29) (Table S3). This unsupervised 
clustering classified the protein groups into four distinct clusters according to their expression profile. 
Cluster 1 (n=1189) and Cluster 4 (n=668) included proteins that increased their expression with ageing, 
while Cluster 2 (n=1167) and Cluster 3 (n=966) included proteins that were decreased with ageing (Fig. 
4F). We then used GO analysis to determine whether these profile clusters encompassed distinct 
biological processes. As expected, ageing was one of the most enriched GO Biological processes in 
cluster 1 and 4 (Fig. 5A). In addition, we also observed many of the hallmarks of ageing (47), including 
decreased levels of proteins involved in the maintenance of stem cell populations (e.g. SOX2 and 
SOX9) (Fig. 5B), chromatin remodelling (e.g. CHD7and ARID1) (Fig. 5C), cell cycle control (e.g. CDK1 
and CDK2) (Fig. 5D) and in DNA repair (e.g. H2AFX or NUDT1) (Fig. 5E), as well as an increase in 
expression of proteins involved in cancer pathways (e.g. NRAS or KRAS) (Fig. 5F). 
 
Cluster 1 includes proteins that increase their expression once development is completed with little 
change during adulthood. This cluster contains proteins involved in oxidative phosphorylation, 
neurotransmitter secretion and metabolism. It also includes proteins associated with the classical 
neurodegenerative diseases, Alzheimer’s disease (AD) such as MAPT or NOS1, Parkinson’s disease (PD) 
like SNCA or cytochrome c oxidase complex proteins and Huntington’s disease (HD) such as HAP1. 
Cluster 4 comprised proteins that increase in expression from development and through ageing. This 
cluster includes proteins associated with immune responses, endocytosis, regulation of actin 
cytoskeleton, and autophagy, and are located mainly in the plasma membrane, exosome and 
lysosome.  Cluster 2 consists of proteins that are decreased after development and remain similar 
through adulthood and includes proteins involved in mRNA splicing, transcription, translation, and 
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DNA repair, which are located mainly in the nucleoplasm, nucleolus, spliceosomal complex and 
ribosome subunits. Cluster 3 includes proteins that decrease with ageing. These are proteins involved 
in DNA replication, cell division, brain development and stem cell population maintenance and are 
located mainly in the nucleus and chromatin. The complete GO annotation and KEGG pathway analysis 
for each cluster is represented using heatmaps in Fig. S3, S4, S5, S6 and Table S4. In the heatmap, 
annotation terms significantly enriched in each cluster when compared to the total proteome are 
represented in each line, then the fold enrichment in each cluster is represented. Yellow represents a 
high-fold enrichment while purple represents a low-fold enrichment.   
 
The GO term immune response was the most enriched term in Cluster 4 (Fig. S3 and S4, Table S4), 
indicating that aged OPCs acquire expression of proteins associated with immune functions in 
homeostasis such as CD74, B2M or TAP1. This aligns with RNA sequencing data (14, 15) and is common 
with other adult stem cells (48, 49). The expression of immune-associated proteins and functions in 
OPCs have previously being shown in adult OPCs in response to demyelination in toxin-induced 
models (2), experimental autoimmune encephalomyelitis (EAE) (50, 51) and in MS lesions (52). We 
cannot entirely exclude the possibility that this is due to immune cell contamination of our samples, 
but since the levels of microglia and red blood cell contamination were similar in both adult OPCs 
preparations (Fig. 1B), these data suggest an OPC subpopulation with an immune-associated profile.  
 
Protein expression changes between young and aged adult OPCs 
Remyelination is a highly efficient process in young adults, but its efficiency declines with ageing (5, 
10, 15). To explore differences that might contribute to the aged-related decline in remyelination we 
compared the log2 intensity of the 6842 proteins present in at least 5 biological replicates detected in 
young and aged OPCs. We detected 659 proteins with a significant expression change (FDR 5%): 319 
proteins were increased, while 340 were decreased in aged OPCs compared to young adult OPCs 
(Table S5). GO analysis revealed that increased proteins are involved in positive regulation of TOR 
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signalling, actin polymerization or depolymerization, catabolic processes and autophagy, while 
decreased proteins are involved in retinol metabolism, responses to metal ions and mitotic nuclear 
division (Fig. S7). Of the 659 proteins, only 89 had a greater than 1.5-fold change in expression (Table 
S4). Of those 89 proteins, 67 were increased and were related to autophagy, immune responses and 
thyroid hormone signalling, while 22 were decreased and were involved with responses to organic 
substances or retinol metabolism (Fig. 6A).  
 
Amongst the proteins decreased in aged OPCs are proteins involved in actin stabilization (e.g. 
SPTAN1); ALDH1A1, the enzyme responsible for the synthesis of 9-cis-retinoic acid and which 
promotes OPC differentiation during CNS remyelination (38); enzymes involved in matrix 
mineralization (e.g. ALPL (alkaline phosphatase))(53); FOLR1, mutations in which have been linked to 
myelination deficits (54); and TCF4, which is involved in stage-specific regulation of OPC differentiation 
(55). Conversely, lysosomal enzymes (e.g. LAMTOR3, LAMP1, LAMP2, NPC1, NPC2) and cathepsins 
(e.g. CTSD, CTSB, CTSE, CTSH, CTSS, CTSZ), together with enzymes involved in the sphingolipid 
synthesis and modification of proteins such as citrullination (e.g. ARSB, PSAP, PPT1, ASAH1 AND 
PADI2) are increased in aged OPCs (Fig. 6B, Table S5).  
 
Changes in the myelin sheath components within aged OPCs 
Aged OPCs exhibited not only a decrease in proteins involved in stem cell maintenance (Fig. 5B) but 
also an increase in myelin proteins characteristic of differentiated oligodendrocytes (Fig. 7A, B, C and 
D and Fig. S8). PLP, MOG, MOBP, MBP and CNP showed a trend towards an increase in expression in 
aged OPCs by western blot but this trend was not significant, probably due to a lower sensitivity of 
the western blot to detect the subtler changes in the OPCs. On immunohistochemistry, CLDN11 (Fig. 
7C, D) (Kruskal-Wallis p=0.0274*, Dunn’s Multiple comparison test neonatal vs young p=0,9999, 
neonatal vs aged p=0.0412*, young vs aged p=0.2813) was significantly increased with ageing, while 
MOBP (Fig. 3D, E), MOG (1-way ANOVA p=0.3087) (Fig. 7C, D), MBP (Kruskal Wallis p=0.1097) and CNP 
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(1-way ANOVA p=0.5790) (Fig. S8B) were not significant. This increase in myelin protein expression in 
OPCs with ageing is unlikely to be caused by oligodendrocyte contamination during the isolation 
process since both preparations of adult OPCs contained only 2% A2B5+MOG+ cells and 0.4% A2B5–
MOG+ cells (Fig. 1B). Moreover, the expression of PLP (1-way ANOVA p=0.3557), MOG (1-way ANOVA 
p=0.0012**), MOBP (1-way ANOVA p=0.0458*), CNP (Kruskal-Wallis p=0.0187*) and MBP (Kruskal-
Wallis p=0.0231*) in aged OPCs was at considerably lower levels than those associated with mature 
oligodendrocytes (Figs. 7B, S8A) (56, 57). 
 
Important changes in the expression of enzymes involved in cholesterol biosynthesis also occurred 
with OPC ageing. Cholesterol synthesis enzymes (e.g. HMGS1, HMGS2, HMGR, DHCR7, DHCR24) and 
the rate limiting enzyme for the synthesis of cholesterol, FDFT1 ((58) are significantly decreased in 
adult OPCs compared to neonatal OPCs (Fig. 7E). In contrast, proteins involved in the intracellular 
transport of cholesterol (e.g. NPC1 and NPC2), as well as APOE, the main protein responsible for 
cholesterol transport in the CNS, were higher in aged OPCs (Fig. 7F). This may be related to the 
completion of developmental myelination, since following this process cholesterol synthesis is 
decreased by around 85% (59).   
 
High-throughput proteomics suggests links between aged OPCs and neurodegenerative diseases 
Ageing is the highest risk factor for the development of several neurodegenerative diseases such as 
Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD). Most of these 
diseases are characterised by the misfolding and deposition of proteins such as amyloid-b, tau, a-
synuclein, TDP-43 and huntingtin. While most research has focused on protein accumulation in 
neurons, several recent publications suggest that other cell types such as microglia, astrocytes, 
pericytes and oligodendrocytes are also involved in the development of neurodegenerative diseases 
(60-66).  
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A striking feature in the KEGG pathways analysis of our data was the enrichment of proteins associated 
with AD, PD and HD in Cluster 1, the cluster that includes proteins that are increased in young and 
aged OPCs compared to neonatal OPCs (Fig. 8A, Fig. S4). Adult (young and aged) OPCs show higher 
expression than neonatal OPCs of some of the proteins associated with AD, PD, HD and MS (e.g. TAU 
(67, 68), APOE (69), CRYAB (70-73), TPPP (74) and SNCA (75, 76) (Fig. 8B).  
 
Dysregulation of the normal mechanisms by which aggregates of misfolded proteins are cleared 
involving the proteasome, autophagy and chaperone-mediated refolding/degradation is associated 
with neurodegeneration (47). We found that aged OPCs also have an altered protein homeostasis 
system. For example, heat shock proteins HSPD1 and HSPA9, as well as autophagy and lysosome-
related proteins are increased with ageing (Fig. 8D, E, F), in contrast to the previously described age-
associated decline in autophagy and lysosomes (77). On the other hand, the proteasome proteins and 
proteins involved in the control of protein folding are significantly decreased in aged OPCs (Fig. 8C, 
G). The decreased expression of proteasome and protein folding-associated proteins was further 
validated by western blot and immunohistochemistry. Western blot data showed that the expression 
of proteasome 19S was decreased in young and aged OPCs when compared to neonatal OPCs (Fig. 
9A). Moreover, expression of the proteasome 20S as well as prefoldin subunit 5 (PFDN5), a molecular 
chaperone that binds and stabilizes newly synthesize proteins allowing them to fold correctly, was 
also examined by immunohistochemistry (Fig. 9B). Both, proteasome 20S (Kruskal-Wallis 
p=<0.0001****, Dunn’s Multiple Comparison test 6m vs 12m p<0.0001****, 6m vs 12m 
p<0.0001****, 12m vs 18m p=0.9999) and PFDN5 (Kruskal-Wallis p=<0.0001****, Dunn’s Multiple 
Comparison test 6m vs 12m p<0.0001****, 6m vs 12m p<0.0001****, 12m vs 18m p=0.1069) 
decreased expression (measured as mean intensity of the protein per PDGFRa+ cell) in OPCs at 12 or 
18 months of age when compared to OPCs at 6 months of age. However, no differences were detected 
in proteasome 20S or PFDN5 between 12 and 18 months old OPCs (Fig. 9C). These data suggest that 
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aged OPCs may also be vulnerable to the deleterious consequences of aggregation-prone proteins and 
therefore have a potential role in other neurodegenerative diseases.  
 
DISCUSSION 
 
Recent efforts to understand the molecular changes occurring in the ageing brain have often used 
large-scale transcriptome analysis (2, 12-14, 42, 78, 79).  In contrast, there are relatively few proteome 
data sets relating to brain cell type specific expression patterns (17), myelin (80), OPC differentiation 
to oligodendrocytes (19), ES differentiation into OPCs (18) or developmental changes in neurons (81). 
Although transcriptomic studies provide valuable insights, most transcripts require translation to 
protein to deliver biological function of the expressed gene. In addition, translation of a gene can be 
altered at different stages, including initiation, elongation or termination by a range of mechanisms. 
Translational regulatory mechanisms can affect mRNAs globally, or can affect a subset of mRNAs or a 
specific mRNA influencing mRNA to protein transition. For example, mRNAs can be sequestered to in 
stress granules or P bodies limiting their accessibility, translation initiation factors such as eIF2a can 
be subjected to post-translational modifications affecting the ability of Met-tRNAi binding to 
ribosomes, trans-binding proteins can bind to mRNA inhibiting translation initiation and microRNAs 
can lead to a series of RNA degradative mechanisms (82). The different translational regulatory 
mechanism can thwart mRNA translation, leading to a poor correlation between transcriptome and 
proteome. As such, protein expression studies are critical to define the functional state of cell 
populations. To better understand the age-linked protein changes in OPCs that may contribute to 
remyelination failure in MS, we performed a proteome analysis of OPCs from neonatal, young adult 
and aged rats using a relative quantitative approach that allowed comparison of OPC protein 
expression levels across the three age groups. We used ex vivo freshly isolated OPCs to avoid in vitro 
artefacts and culture-based selection of “fittest” cells based on the environment provided. Although 
relatively pure OPC populations from the neonatal CNS can be isolated and grown in tissue culture, 
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the same is not true of adult and especially aged OPCs, the culturing of which is notoriously 
challenging. Despite the high purity obtained in neonatal OPCs (90% A2B5+ cells), the same isolation 
methodology used for young and aged tissue renders a population significantly enriched in OPCs but 
with a higher microglia and red blood cell contamination. Therefore, despite the very stringent “cut-
off” for downstream analysis, we caution that some of the altered protein expression may be due to 
other cell type contaminants rather than intrinsic changes in OPCs per se.  
 
One of the most striking features of the ageing OPC proteome is that neonatal OPCs differ in 
approximately 50% of the proteome from their young and aged counterparts. This difference raises 
an important point for experiments related with the therapeutic targeting of OPC differentiation as a 
treatment for MS. Despite MS being largely a disease of adulthood and ageing, most in vitro 
differentiation assays have focused on developmental OPCs (40, 83-85). Therefore, when screening 
for pro-differentiating agents it is necessary to validate findings obtained with neonatal OPCs using 
(aged) adult OPCs and in vivo, especially taking to account that MS is a disease of adulthood. The 
proteomes of young and aged OPCs were highly correlated, with 659 proteins significantly altered and 
only 89 proteins showing more than a 1.5 fold change. Despite the large number of proteins detected, 
the ageing OPC proteome is not complete in our samples: low abundance proteins such as 
transcription factors are underrepresented and the analysis of the different isoforms as well as the 
potential changes in post-translational modifications such as phosphorylation, citrullination or 
ubiquitination have not been assessed.  
 
In common with other adult stem cells (56, 57), adult OPCs not only decrease the expression of 
proteins involved in stem cell maintenance, but also acquire a higher expression of proteins known to 
be markers of the terminal state of their lineage, the mature oligodendrocytes. These data suggest 
that with ageing, OPCs undergo a degree of differentiation ‘drift’, despite their ability to give rise to 
new oligodendrocytes being impaired with aging (9, 10). We also observed that unlike myelin proteins, 
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cholesterol biosynthesis related enzymes were decreased after development and in the aged OPCs, 
as described for aged astrocytes (86). In addition, aged phagocytes have a reduced capacity to clear 
and recycle cholesterol back to the extracellular space (8), which may contribute to the diminished 
cholesterol availability in the aged brain. This reduced cholesterol availability may influence the 
capacity of aged OPCs to differentiate into myelinating oligodendrocytes and contribute to age-
related remyelination failure. Cholesterol supplementation in the diet increases the thickness of 
myelin during remyelination in mice that were 8-10 weeks of age suggesting that OPCs behaviour is 
influenced by dietary cholesterol (87). This reduction in cholesterol together with the enhanced 
expression of myelin proteins may also be key not only for age-associated remyelination failure but 
also for new myelinating oligodendrocyte formation during myelin plasticity (88-90).  
 
A feature of ageing populations is the rise in the number of people with neurodegenerative diseases 
such as AD and PD. OPCs play a key role in primary conditions of myelination, but their role in classical 
neurodegenerative diseases is little explored. Our proteome analysis showed that aged OPCs 
increased the expression of proteins involved in AD, PD or HD and have an altered protein homeostasis 
system suggesting a potential accumulation of protein aggregates like those prevalent in ageing 
neurons. AD patients and AD mouse models show white mater alterations, fewer Olig2+ cells  (64, 91-
93) and an increased number of senescent OPCs associated with amyloid plaques (94). Moreover, 
aged OPCs have a higher expression of proteins like CRYAB and QDPR, similar to that which occurs in 
OPCs and oligodendrocytes from AD patients (73). Multiple system atrophy (MSA), is characterised by 
abnormal accumulation of α-synuclein in oligodendrocytes that causes myelin and neuron 
degeneration (65, 95). The overexpression of α-synuclein in stem cell-derived oligodendrocytes 
impairs myelin formation (96) and its aggregates interfere with the expression of myelination 
associated mRNAs in vitro (97). Our data suggests that the α-synuclein aggregates in OPCs (97, 98) 
increase with ageing, potentially contributing to OPC differentiation impairment. Moreover, the 
aggregation of misfolded proteins may play a key role in altering the basal energy state of the cell and 
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therefore contribute to age-associated remyelination failure. Misfolded protein aggregation might 
arise in aged OPCs due to the increased expression of PADI2, an enzyme responsible for the 
citrullination of different proteins in the brain that has also been recently implicated in OPC 
differentiation (99).  The changes in positive charges of proteins like MBP, due to the conversion of 
arginine into citrulline, changes their structure leading to increased demyelination (100), pronounced 
denaturation and protein misfolding (101). Therefore, citrullination is  considered a hallmark of 
different neurodegenerative diseases (102-104). Moreover, MBP citrullination has been recently 
shown to trigger autoimmune demyelination in a model of MS (105) and its increased expression in 
aged OPCs may therefore contribute to protein aggregation and remyelination failure. In response to 
protein aggregation, an increase in lysosomal and autophagy associated proteins was observed in 
aged OPCs contrary to what has been described in ageing (77). Lysosomes, are also considered primary 
sensors of the cell state, as they are able to sense energy metabolic state and are a component of 
primary nutrient sensing pathway. Therefore, the increase in lysosomal proteins in aged OPCs could 
be associated with increased OPC quiescence. As lysosomes are key in maintaining neural stem cell 
quiescence (106), a dysregulation and accumulation of storage material in the cell that requires 
increase lysosome biogenesis (107, 108)  as occurs in neuronal lipofuscinosis, could signal OPC 
senescence. Thus, this change reflect an adaptation of the lysosome to changes in the energy state of 
aged OPCs or to a higher inflammatory environment, similar to that shown in activated phagocytes, 
cancer cells and other inflammatory diseases (109-111). These increases in lysosomes and autophagy 
could also be a cell-intrinsic compensatory mechanism in response to ageing cues (77). However,  
changes in lysosomal proteins do not necessarily always correlate with lysosomal function as shown 
for neurons in models of AD (112). 
 
In summary, the analysis of the proteome of OPCs in the context of ageing provides a unique tool to 
understand the protein changes that underlie age-associated remyelination failure, and potentially 
other physiological and pathophysiological roles of these abundant and widely distributed CNS cells. 
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We observed key changes in proteins involved in metabolism, immune response and actin 
cytoskeleton that may influence OPC remyelination biology. In addition, the study of the OPC 
proteome in the context of ageing provides new indications that OPCs, and the alterations they 
undergo with ageing, may be relevant for the development of other neurodegenerative diseases.  
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FIGURE LEGENDS 
 
Figure 1: Validation of OPC isolation method and overview of the ageing OPC proteome. (A) Boxplot 
showing the log2 protein intensity for PDGFRA in neonate, young and aged OPCs (n=6). (B) Graph 
showing flow cytometric analysis of purity of freshly isolated OPCs at the three different ages shown 
as a percentage of live cells (n=4, mean ± s.e.m. shown, statistics shown for A2B5+MOG, Kruskal-Wallis 
p = 0.038*, Dunn’s Multiple test comparison between neonate and young p=0.0172, neonate and old 
p=0.34 and young and old p=0.60). (C) Scatter plot showing the correlation of the log2 changes of all 
protein groups amongst the 2 multiplexes. (D) Graph showing the number of protein groups detected 
per age group. A total of 7481 protein groups were detected with 1% FDR. (E) Venn diagram of the 
proteins identified with high confidence in multiplex. (F, G) Graphs showing the relationship between 
protein level and transcript level  for young (F) and aged (G) OPCs.  Scatter plots show the 
representation of the correlation coefficients (Biweight midcorrelation coefficient) and the 
corresponding adjusted p-values of significance (p-values were plotted as negative log10. Threshold 
(red dotted line) corresponds to FDR adjusted p value 0.05). Boxplots show the distribution of 
correlation coefficients for each detected protein.  
 
Figure 2: Expression of OPC cell markers. (A) Boxplots displaying the log2 protein intensity for 
oligodendrocyte lineage cell markers OLIG2 and SOX10 in neonate, young and aged OPCs (n=6). (B) 
Boxplots showing the log2 protein intensity of various OPC specific markers in the three age groups 
(n=6). 
 
Figure 3: Validation of the ageing proteome. (A) Heatmap showing the Z score expression of 4 
randomly chosen proteins. Z score was calculated and heatmaps indicates the mean Z score for the 
six independent biological replicates of the proteomics dataset. Lower expression is represented in 
blue, and higher expression is shown in yellow. (B) Western blot images validating the proteome 
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expression analysis in acutely isolated OPCs (n=3-6, mean ± s.e.m. shown) (C) Graphs show the 
densitometry quantification for PADI2, CRYAB, MOBP and FABP (n=3-4). (D, E) Immunocytochemistry 
validation and quantification of the intensity of selected proteins per A2B5+ cell after 7 DIV. Scale bar 
100µm (n=3, mean ± s.e.m. shown). 
 
Figure 4: The neonatal OPC proteome is significantly different to the adult OPC proteome. (A) Principal 
component analysis (PCA) plot showing the segregation of neonate, young and aged OPC proteomes 
on components 1 and 2. (B) PCA plot showing the segregation of young and aged OPC proteomes on 
components 1 and 2. (C) Correlation matrix between the biological replicates within and across the 
age groups. Neonatal OPCs show a negative correlation with adult OPCs. (D) Venn diagram of the 
number of common and different proteins showing a significant expression change between neonatal 
vs young, neonatal vs aged, and young vs aged OPCs. (E) Volcano plots illustrating differential 
expression of proteins between neonatal, young and aged OPCs. Coloured proteins are significantly 
regulated with FDR < 0.05. Blue in indicates a Log2 change < (-0.6) (fold change < (-1.5)) while orange 
refers to proteins with Log2 change > 0.6 (fold change > 1.5). (F) Unsupervised fuzzy C-means clustering 
showing the protein dynamics of those proteins with FDR < 0.05 and more than 1.5 fold change 
expression when compared to neonatal OPCs with n representing the number of proteins per cluster.   
 
Figure 5: OPCs show classic ageing hallmarks. Heat maps showing the mean Z score per age group for 
proteins associated with ageing (A), stem cell maintenance (B), chromatin remodelling (C), cell cycle 
(D), DNA repair (E) and cancer pathways (F). Row Z score indicates the mean of six independent 
biological replicates and lower expression is represented in blue, and higher expression is in yellow. 
 
Figure 6: Proteome changes between young and aged OPCs. (A) Bar graph showing the GO Biological 
processes that are enriched amongst those proteins that have an FDR<0.05 and more than 1.5 FC 
between young and aged OPCs. Orange represents the GO terms enriched amongst the proteins 
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upregulated (orange) and downregulated (blue) in aged OPCs. (B) Volcano plot illustrating differential 
expression of proteins between young and aged OPCs. Coloured proteins are significantly regulated 
with FDR < 0.05. Blue in indicates a Log2 change < (-0.6) while orange refers to proteins with Log2 
change >0.6. The names of the significantly regulated proteins are included in the volcano plot.  
 
Figure 7: Changes in myelin proteins and cholesterol metabolism related proteins in aged OPCs. (A) 
Heat map showing the increased expression of myelin proteins in aged OPCs. Z score indicates the 
mean of six independent biological replicates of the proteomics dataset. Lower expression is 
represented in blue, and higher expression is shown in yellow. (B) Representative Western blot 
showing myelin protein expression in A2B5+ OPCs and MOG+ oligodendrocytes from different ages. 
(C) Representative immunocytochemistry images of purified OPCs cultured for 6 days in vitro and 
immunostained for CLDN11 and MOG. (D) Bar graphs indicating IHC quantification of myelin protein 
intensity per A2B5+ cells across the different age groups (each biological replicate is represented by a 
single dot) Scale bar 100µm (n=3, mean ± s.e.m. shown). (E, F) Heat maps showing the expression 
changes for proteins involved in cholesterol biosynthesis or cholesterol transport, respectively. Z score 
indicates the mean of six independent biological replicates and lower expression is shown in blue, and 
higher expression is shown in yellow.  
 
Figure 8: Loss of proteostasis in aged OPCs and links to other neurodegenerative diseases. (A) Bar 
graph showing the KEGG pathway enrichment of terms associated with neurodegenerative diseases 
within cluster 1. (B-G) Heat maps showing the expression changes for proteins in OPCs for proteins 
involved in (B) different neurodegenerative diseases, (C) proteasome, (D) lysosome, (E) autophagy, (F) 
heat shock and (G) protein folding related proteins, respectively. Z score indicates the mean of six 
independent samples per age group; lower expression is represented in blue, and higher expression 
is shown in yellow. 
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Figure 9: Proteasome 19S and 20S and protein folding protein PFDN5 expression is decreased in aged 
OPCs. (A) Western blot showing the expression of proteasome 19S in neonatal, young and aged OPCs. 
Three replicates per age are loaded in each case (n=3). (B) Immunohistochemistry of 6-month-old 
brains showing the expression of proteasome 20S and PFDN5 (red) in OPCs identified by the 
expression of Olig2 (green) and PDGFRa cells (grey). Yellow arrows indicate examples of OPCs 
expressing either 20S or PFDN5. Scale bar 100µm. (C) Violin plots showing the quantification of the 
mean intensity for 20S and PFDN5 per PDGFRa+ cell. Each dot represents 1 cell and the red line 
represents the median intensity across the different cells in each age (n=2 animals per age; for 20S 
n=233 (6m), n=287 (12m) and n=264 (18m) and for PFDN5 n=132 (6m), n=143 (12m) and n=115 (18m) 
cells have been quantified per age). 
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